Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators

被引:0
|
作者
Merlino, Francesco [1 ,2 ]
Secondo, Agnese [3 ]
Mitidieri, Emma [1 ]
Sorrentino, Raffaella [1 ]
Bellavita, Rosa [1 ]
Grasso, Nicola [1 ]
Chatenet, David [4 ]
Pannaccione, Anna [3 ]
Grieco, Paolo [1 ,2 ]
Bianca, Roberta d'Emmanuele di Villa [1 ]
Carotenuto, Alfonso [1 ,2 ]
机构
[1] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, I-80131 Naples, Italy
[2] Univ Naples Federico II, Ctr Interuniv Ric Peptidi Bioattivi Carlo Pedone C, I-80134 Naples, Italy
[3] Univ Naples Federico II, Sch Med & Surg, Dept Neurosci Reprod & Dent Sci, Div Pharmacol, I-80131 Naples, Italy
[4] Univ Quebec, Inst Natl Rech Sci INRS, Ctr Armand Frappier Sante Biotechnol, Quebec City, PQ H7V 1B7, Canada
关键词
ANTAGONIST PALOSURAN; URANTIDE; BINDING; P5U; EXPRESSION; DISCOVERY; IMPROVES; LIGANDS; INSIGHT; CELLS;
D O I
10.1021/acs.jmedchem.4c00688
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
While the urotensinergic system plays a role in influencing various pathologies, its potential remains untapped because of the absence of therapeutically effective urotensin II receptor (UTR) modulators. Herein, we developed analogues of human urotensin II (h U-II) peptide in which, along with well-known antagonist-oriented modifications, the Glu1 residue was subjected to single-point mutations. The generated library was tested by a calcium mobilization assay and ex vivo experiments, also in competition with selected ligands. Interestingly, many derivatives showed noncompetitive modulation that was rationalized by the lateral allostery concept applied to a G protein-coupled receptor (GPCR) multimeric model. UPG-108 showed an unprecedented ability to double the efficacy of h U-II, while UPG-109 and UPG-111 turned out to be negative allosteric modulators of UTR. Overall, our investigation will serve to explore and highlight the expanding possibilities of modulating the UTR system through N-terminally modified h U-II analogues and, furthermore, will aim to elucidate the intricate nature of such a GPCR system.
引用
收藏
页码:13879 / 13890
页数:12
相关论文
共 42 条
  • [41] Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)
    Xu, Lianhong
    Liu, Hongtao
    Hong, Allen
    Vivian, Randy
    Murray, Bernard P.
    Callebaut, Christian
    Choi, You-Chul
    Lee, Melody S.
    Chau, Jennifer
    Tsai, Luong K.
    Stray, Kirsten M.
    Strickley, Robert G.
    Wang, Jianhong
    Tong, Leah
    Swaminathan, Swami
    Rhodes, Gerry R.
    Desai, Manoj C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (03) : 995 - 999
  • [42] N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetarnido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy
    Zhang, Hao
    Xu, Lijuan
    Qin, Xia
    Chen, Xiaofei
    Cong, Hui
    Hu, Longmiao
    Chen, Long
    Miao, Zhenyuan
    Zhang, Wannian
    Cai, Zhenyu
    Zhuang, Chunlin
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (14) : 6665 - 6681